Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The prognosis for older individuals with acute myelogenous leukemia (AML) has been
historically poor, with 2 year disease-free survival rates < 20% reported. Younger patients
with AML in first complete remission are routinely treated using a full intensity
(myelo-ablative) chemotherapy followed by a blood stem cell transplant. For the older patient
with AML, full intensity therapy transplants have been greatly limited by increased rates of
toxic effects related to this type of conditioning regimen. Reduced intensity
(non-myeloablative) conditioning regimens have been used in a number of clinical settings,
including AML therapy, to lessen the regimen related toxicity in the older patient. Recent
data from the University of Michigan Blood and Marrow Transplant Program suggests improved
survival for individuals > 55 years in age undergoing reduced intensity, transplants from
unrelated donors. This study will investigate the safety and efficacy of this treatment
option for older patients with AML, with the primary goal being to improve the survival and
lifespan for older patients with AML.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center